USD10
AVTX Shares
About Avalo TherapeuticsAvalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).
USD10
AVTX Shares
About Avalo TherapeuticsAvalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).
Stats
TRADING WINDOW
Closed
OPENS AT
Mar 20 at 1:30 PM GMT+0
MARKET CAP
$248.44M
OPEN PRICE
$13.94
LOW (1Y)
$3.39
HIGH (1Y)
$20.72
LOW (24H)
$13.19
HIGH (24H)
$14.80
VOLUME (24H)
$477.51K
45.02%
Price history
Time | Price | Change |
|---|---|---|
Today | $13.94 | |
1 Day | $14.69 | |
1 Week | $16.34 | |
1 Month | $13.91 | |
1 Year | $7.66 |